Top Page
Immunotech Biopharm Ltd
(6978)
Immunotech Biopharm Ltd (6978) vs. iShares MSCI Hong Kong ETF (EWH)
Immunotech Biopharm Ltd Business Overview & Revenue Model
Immunotech Biopharm Ltd Financial Statement Overview
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | Gross Profit |
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | EBIT |
| -198.78M | -230.55M | -280.24B | -333.35M | -419.83M | EBITDA |
| -148.68M | -178.83M | -236.16M | -324.33M | -333.99M | Net Income Common Stockholders |
| -186.91M | -334.82M | -352.83M | -375.49M | -458.34M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 57.49M | 176.97M | 79.46M | 353.34M | 845.39M | Total Assets |
| 564.04M | 846.28M | 879.44M | 1.10B | 1.21B | Total Debt |
| 116.46M | 457.17M | 149.81M | 111.05M | 51.06M | Net Debt |
| 69.50M | 405.01M | 91.36M | -242.29M | -794.33M | Total Liabilities |
| 580.50M | 675.39M | 373.07M | 274.51M | 81.38M | Stockholders Equity |
| -13.30M | 173.62M | 508.44M | 822.26M | 1.13B |
| Cash Flow | Free Cash Flow | |||
| 0.00 | -186.17M | -277.49M | -435.89M | -339.34M | Operating Cash Flow |
| 0.00 | -163.63M | -180.92M | -254.65M | -263.67M | Investing Cash Flow |
| 0.00 | -116.60M | 23.38M | -328.21M | -204.07M | Financing Cash Flow |
| 0.00 | 273.92M | -36.06M | -11.00M | 1.05B |
Immunotech Biopharm Ltd Technical Analysis
Immunotech Biopharm Ltd Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.32B | 0.30 | -60.36% | 2.39% | 17.47% | 1.73% | |
37 Underperform | HK$1.58B | ― | -228.99% | ― | ― | 44.88% | |
| $12.49B | 28.61 | 8.17% | ― | ― | ― | ||
| €144.60M | ― | -4.30% | ― | ― | ― | ||
58 Neutral | HK$3.28B | 18.36 | 4.47% | ― | -9.75% | ― | |
55 Neutral | HK$81.95B | ― | -8.98% | ― | -54.66% | -123.11% | |
52 Neutral | HK$32.10B | ― | -19.78% | ― | 25.96% | 39.58% |
Immunotech Biopharm Ltd Corporate Events
Immunotech Biopharm Ltd has announced its upcoming Annual General Meeting (AGM) scheduled for May 23, 2025, in Beijing, China. The meeting will address several key resolutions including the adoption of financial statements, re-election of directors, and granting a mandate to the board for share issuance. These resolutions are crucial for the company’s governance and strategic planning, potentially impacting its market operations and investor relations.
Immunotech Biopharm Ltd has announced a change in its board of directors, with Ms. Yu Xiaohui appointed as a non-executive director and a member of the audit committee, replacing Mr. Tao Ran who resigned due to other job arrangements. This leadership change reflects the company’s ongoing strategic adjustments and may influence its future direction in the pharmaceutical sector.
Immunotech Biopharm Ltd has announced the composition of its board of directors and the roles within its established committees. This organizational update reflects the company’s commitment to strong governance and strategic leadership, potentially impacting its operational efficiency and stakeholder confidence.
Immunotech Biopharm Ltd announced its annual results for the year ended December 31, 2024, highlighting significant financial improvements. The company reported a substantial increase in other income and a notable decrease in losses before tax and total comprehensive expenses. Additionally, research and development, as well as administrative expenses, saw reductions. On the business front, the company made progress in its clinical trials, with EAL® receiving priority review in China and the conditional NDA being accepted. The 6B11-OCIK Injection completed Phase I trials, with plans to proceed to Phase II. These developments indicate a positive trajectory for the company’s operations and potential growth in the biopharmaceutical sector.
Immunotech Biopharm Ltd announced that the conditional new drug application for its core product candidate, EAL®, has been accepted by the Centre for Drug Evaluation of the National Medical Products Administration of China. EAL® is a multi-target cellular immunotherapy product with a decade-long track record in treating various cancers. This acceptance marks a significant step for the company in advancing its product pipeline and potentially strengthens its position in the biopharmaceutical industry, although future approvals and successful marketing are not guaranteed.
Immunotech Biopharm Ltd has announced the postponement of its board meeting initially scheduled for March 28, 2025, to March 31, 2025. This delay is due to the need for additional time to finalize the company’s annual results for the year ending December 31, 2024, which could impact the company’s reporting schedule and stakeholder expectations.
Immunotech Biopharm Ltd has announced that its board of directors will meet on March 28, 2025, to consider and approve the company’s annual results for the year ending December 31, 2024. This meeting is crucial as it will determine the financial performance of the company and could influence its market positioning and stakeholder confidence.
Immunotech Biopharm Ltd has announced that it is preparing to submit an application for conditional approval of its core product candidate, EAL®, to the Center for Drug Evaluation of the National Medical Products Administration in China. EAL® is a multi-target cellular immunotherapy product used in cancer treatment, and the company has completed Phase II clinical trials with 430 patients. The submission will be subject to rigorous evaluation, and there is no guarantee of approval, but this step represents a significant development in the company’s efforts to bring EAL® to market.